ENZO BIOCHEM INC's ticker is ENZ and the CUSIP is 294100102. A total of 108 filers reported holding ENZO BIOCHEM INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $37,000 | -84.4% | 13,600 | -68.7% | 0.00% | -80.0% |
| Q1 2018 | $237,000 | -32.9% | 43,400 | 0.0% | 0.02% | -21.1% |
| Q4 2017 | $353,000 | +31.7% | 43,400 | +69.5% | 0.02% | +35.7% |
| Q3 2017 | $268,000 | +10.7% | 25,600 | -11.7% | 0.01% | -6.7% |
| Q1 2017 | $242,000 | -64.4% | 29,000 | -70.4% | 0.02% | -73.2% |
| Q4 2016 | $680,000 | +5.4% | 98,000 | -22.8% | 0.06% | +7.7% |
| Q3 2016 | $645,000 | +9.0% | 126,900 | +27.9% | 0.05% | -5.5% |
| Q2 2016 | $592,000 | +180.6% | 99,200 | +113.3% | 0.06% | +161.9% |
| Q1 2016 | $211,000 | +1.0% | 46,500 | 0.0% | 0.02% | -22.2% |
| Q4 2015 | $209,000 | +221.5% | 46,500 | +109.5% | 0.03% | +200.0% |
| Q1 2015 | $65,000 | -77.5% | 22,200 | -65.9% | 0.01% | -81.6% |
| Q4 2014 | $289,000 | -27.9% | 65,100 | -16.4% | 0.05% | -18.3% |
| Q3 2014 | $401,000 | +201.5% | 77,900 | +206.7% | 0.06% | +200.0% |
| Q2 2014 | $133,000 | +26.7% | 25,400 | 0.0% | 0.02% | +25.0% |
| Q1 2014 | $105,000 | – | 25,400 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Roumell Asset Management, LLC | 2,886,771 | $10,219,000 | 13.54% |
| HARBERT FUND ADVISORS, INC. | 5,175,913 | $18,323,000 | 6.51% |
| Evermore Global Advisors, LLC | 1,730,607 | $6,126,000 | 5.39% |
| VIEX Capital Advisors, LLC | 1,510,401 | $5,347,000 | 3.24% |
| KEMPNER CAPITAL MANAGEMENT INC. | 25,475 | $90,000 | 0.05% |
| RBF Capital, LLC | 250,359 | $886,000 | 0.05% |
| CORRADO ADVISORS, LLC | 19,366 | $69,000 | 0.04% |
| Cutter & CO Brokerage, Inc. | 27,827 | $99,000 | 0.02% |
| Ergoteles LLC | 177,048 | $627,000 | 0.02% |
| FULLER & THALER ASSET MANAGEMENT, INC. | 941,760 | $3,334,000 | 0.02% |